Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

A new biological switch to slow atherosclerosis progression

28

Apr 2026

A new biological switch to slow atherosclerosis progression

A study by researchers at Baylor College of Medicine and collaborating institutions reveals a previously unrecognized way blood vessels can protect themselves from damage and slow the development of atherosclerosis. The findings, published in the Proceedings of the National Academy of Sciences, have implications for both vascular precision medicine and the safety of certain emerging cancer treatments.

FINGERS-7B built to eradicate Alzheimer's symptoms

28

Apr 2026

FINGERS-7B built to eradicate Alzheimer's symptoms

Alzheimer's disease is best addressed as early as possible, ideally before symptoms become apparent. To enable early, accurate risk prediction both for individuals and whole populations, a team of AI researchers, physicians, and scientists centered at MIT has released FINGERS-7B, the first AI foundation model built to make Alzheimer's preventable.

Modeling the synergy of maternal screening and newborn HBV vaccination

28

Apr 2026

Modeling the synergy of maternal screening and newborn HBV vaccination

Hepatitis B virus (HBV) infection acquired at birth or during early infancy can lead to lifelong health complications, including chronic liver disease. Despite longstanding recommendations for prenatal screening, an estimated 12% to 16% of pregnant individuals in the US are not screened for hepatitis B. This gap leaves a portion of newborns at risk for undetected exposure.

New insights into predicting myeloma drug response

28

Apr 2026

New insights into predicting myeloma drug response

Although patients with the same cancer diagnosis may respond very differently to treatment, clinicians still have limited tools at their disposal to predict who is most likely to benefit or suffer from a particular myeloma therapy.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.